Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $8 price target The firm believes Adial has the potential to outperform over the next 12 months, saying its ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...

Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...

SAIHEAT Limited (f/k/a SAI.TECH Global Corporation) ("SAIHEAT” or the "Company”) (NASDAQ: SAIH, SAITW) is pleased to unveil the SAIHEAT BASE PLAN 2029, an ambitious initiative delivering integrated ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 78,900 shares, a ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...

PERTH, Australia, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) ("Locafy” or the "Company”), a globally recognized software-as-a-service technology company specializing in ...

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for ...